Trade Names:Navane- Capsules 2 mg- Capsules 5 mg- Capsules 10 mg- Capsules 20 mg
Trade Names:Thiothixene- Capsules 1 mg
Produces antipsychotic effects, apparently because of dopamine-receptor blocking in CNS.
Management of schizophrenia.
Circulatory collapse; comatose states; CNS depression due to any cause; blood dyscrasias; hypersensitivity to any component of the product.
PO Start with 2 mg 3 times daily; an increase to 15 mg/day is often effective if needed.Severe ConditionsAdults and Children 12 yr of age and older
PO Start with 5 mg twice daily. The usual optimal dosage is 20 to 30 mg/day. If indicated, an increase to 60 mg/day may be effective. Dosages above 60 mg/day rarely increase the beneficial response.
Store at 68° to 77°F. Protect from moisture. Protect from light.
May cause additive CNS depressant effects.Anticholinergics
May reduce therapeutic effects and increase anticholinergic effects of thiothixene; may lead to tardive dyskinesia.Guanethidine
May inhibit hypotensive effect of guanethidine.Hepatic microsomal enzyme–inducing agents (eg, carbamazepine)
Thiothixene plasma concentrations may be reduced, decreasing the efficacy.Hypotensive agents
Excessive hypotension may result from additive effects.
False-positive pregnancy test results may occur.
Hypotension, light-headedness, nonspecific ECG changes, syncope, tachycardia.
Agitation; cerebral edema; cerebrospinal fluid abnormalities; drowsiness; extrapyramidal symptoms including akathisia, dystonia, and pseudo-parkinsonism; fatigue/weakness; insomnia; paradoxical exacerbation of psychotic symptoms; restlessness; sedation; seizures; tardive dyskinesia.
Increased sweating, photosensitivity, pruritus, rash, urticaria.
Blurred vision, nasal congestion.
Anorexia, constipation, diarrhea, dry mouth, increased appetite, increased salivation, nausea, vomiting.
Amenorrhea, breast enlargement, impotence, lactation, menstrual irregularities.
Elevated alkaline phosphatase, elevated serum transaminases.
Increased weight, peripheral edema.
Anaphylaxis, hyperpyrexia, NMS, polydipsia.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared with taking placebo. Over the course of a 10-wk controlled trial, the rate of death in drug-treated patients was about 4.5% compared with 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either CV (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature.
Patients requiring antipsychotic drug treatment after recovery from NMS should be monitored for recurrence of NMS if thiothixene therapy is reintroduced.
Pregnancy category undetermined.
Safety and efficacy not established in children younger than 12 yr of age.
Use drug with caution in patients with CV disease, seizure disorders, or those exposed to extreme heat.
Agranulocytosis, pancytopenia, and thrombocytopenic purpura have been reported with related drugs.
Drug may impair mental or physical abilities, especially during first few days of therapy.
NMS has occurred with similar agents and is potentially fatal. Signs and symptoms are hyperpyrexia, muscle rigidity, altered mental status, irregular pulse, irregular BP, tachycardia, and diaphoresis.
Potentially irreversible involuntary body and facial movements may occur. Prevalence highest in elderly, especially women.
CNS depression, coma, disturbances of gait, dizziness, drowsiness, dysphagia, hypotension, muscular twitching, rigidity, salivation, torticollis, tremor, weakness.
Copyright © 2009 Wolters Kluwer Health.